Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds

• 主要な著者: Wilke T (著者), Picker N (著者), Müller S (著者), Stürmlinger A (著者), Deiters B (著者), Dittmar A (著者), Aberle J (著者), Gabler M (著者)
• フォーマット: 図書
• 出版事項: Dove Medical Press, 2022-05-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Thomas Wilke,1 Nils Picker,2 Sabrina Müller,2 Anna Stürmlinger,3 Barthold Deiters,4 Axel Dittmar,1 Jens Aberle,5 Maximilian Gabler3 1IPAM e.V., Wismar, Germany; 2Ingress-Health HWM GmbH, Wismar, Germany; 3Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany; 4GWQ ServicePlus AG, Düsseldo...